Mohammed S Al Suraih1,2, Christy E Trussoni3, Patrick L Splinter3, Nicholas F LaRusso3, Steven P O'Hara3. 1. Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA. 2. Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, Minnesota, USA. 3. Division of Gastroenterology and Hepatology, The Mayo Clinic Center for Cell Signaling in Gastroenterology, Mayo Clinic, Rochester, Minnesota, USA.
Abstract
BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by peribiliary inflammation and fibrosis. Cholangiocyte senescence is a prominent feature of PSC. Here, we hypothesize that extracellular vesicles (EVs) from senescent cholangiocytes influence the phenotype of target cells. METHODS: EVs were isolated from normal human cholangiocytes (NHCs), cholangiocytes from PSC patients and NHCs experimentally induced to senescence. NHCs, malignant human cholangiocytes (MHCs) and monocytes were exposed to 108 EVs from each donor cell population and assessed for proliferation, MAPK activation and migration. Additionally, we isolated EVs from plasma of wild-type and Mdr2-/- mice (a murine model of PSC), and assessed mouse monocyte activation. RESULTS: EVs exhibited the size and protein markers of exosomes. The number of EVs released from senescent human cholangiocytes was increased; similarly, the EVs in plasma from Mdr2-/- mice were increased. Additionally, EVs from senescent cholangiocytes were enriched in multiple growth factors, including EGF. NHCs exposed to EVs from senescent cholangiocytes showed increased NRAS and ERK1/2 activation. Moreover, EVs from senescent cholangiocytes promoted proliferation of NHCs and MHCs, findings that were blocked by erlotinib, an EGF receptor inhibitor. Furthermore, EVs from senescent cholangiocytes induced EGF-dependent Interleukin 1-beta and Tumour necrosis factor expression and migration of human monocytes; similarly, Mdr2-/- mouse plasma EVs induced activation of mouse monocytes. CONCLUSIONS: The data continue to support the importance of cholangiocyte senescence in PSC pathogenesis, directly implicate EVs in cholangiocyte proliferation, malignant progression and immune cell activation and migration, and identify novel therapeutic approaches for PSC.
BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by peribiliary inflammation and fibrosis. Cholangiocyte senescence is a prominent feature of PSC. Here, we hypothesize that extracellular vesicles (EVs) from senescent cholangiocytes influence the phenotype of target cells. METHODS: EVs were isolated from normal human cholangiocytes (NHCs), cholangiocytes from PSC patients and NHCs experimentally induced to senescence. NHCs, malignant human cholangiocytes (MHCs) and monocytes were exposed to 108 EVs from each donor cell population and assessed for proliferation, MAPK activation and migration. Additionally, we isolated EVs from plasma of wild-type and Mdr2-/- mice (a murine model of PSC), and assessed mouse monocyte activation. RESULTS: EVs exhibited the size and protein markers of exosomes. The number of EVs released from senescent human cholangiocytes was increased; similarly, the EVs in plasma from Mdr2-/- mice were increased. Additionally, EVs from senescent cholangiocytes were enriched in multiple growth factors, including EGF. NHCs exposed to EVs from senescent cholangiocytes showed increased NRAS and ERK1/2 activation. Moreover, EVs from senescent cholangiocytes promoted proliferation of NHCs and MHCs, findings that were blocked by erlotinib, an EGF receptor inhibitor. Furthermore, EVs from senescent cholangiocytes induced EGF-dependent Interleukin 1-beta and Tumour necrosis factor expression and migration of human monocytes; similarly, Mdr2-/- mouse plasma EVs induced activation of mouse monocytes. CONCLUSIONS: The data continue to support the importance of cholangiocyte senescence in PSC pathogenesis, directly implicate EVs in cholangiocyte proliferation, malignant progression and immune cell activation and migration, and identify novel therapeutic approaches for PSC.
Authors: Dana M Hardbower; Kshipra Singh; Mohammad Asim; Thomas G Verriere; Danyvid Olivares-Villagómez; Daniel P Barry; Margaret M Allaman; M Kay Washington; Richard M Peek; M Blanca Piazuelo; Keith T Wilson Journal: J Clin Invest Date: 2016-08-02 Impact factor: 14.808
Authors: Maria Eugenia Guicciardi; Christy E Trussoni; Anuradha Krishnan; Steven F Bronk; Maria J Lorenzo Pisarello; Steven P O'Hara; Patrick L Splinter; Yandong Gao; Pamela Vig; Alexander Revzin; Nicholas F LaRusso; Gregory J Gores Journal: J Hepatol Date: 2018-05-24 Impact factor: 25.083
Authors: Marco Demaria; Naoko Ohtani; Sameh A Youssef; Francis Rodier; Wendy Toussaint; James R Mitchell; Remi-Martin Laberge; Jan Vijg; Harry Van Steeg; Martijn E T Dollé; Jan H J Hoeijmakers; Alain de Bruin; Eiji Hara; Judith Campisi Journal: Dev Cell Date: 2014-12-11 Impact factor: 12.270
Authors: V Severino; N Alessio; A Farina; A Sandomenico; M Cipollaro; G Peluso; U Galderisi; A Chambery Journal: Cell Death Dis Date: 2013-11-07 Impact factor: 8.469
Authors: Brian A Davies; Leslie O Morton; John R Jefferson; Cody N Rozeveld; Luke C Doskey; Nicholas F LaRusso; David J Katzmann Journal: Mol Biol Cell Date: 2020-08-26 Impact factor: 4.138